ARVC, or arrhythmogenic right ventricular cardiomyopathy, is a genetic heart condition where the muscle of the right ventricle is gradually replaced by scar tissue and fat. This replacement disrupts the heart’s electrical signals and weakens the muscle wall, leading to dangerous irregular heartbeats. It affects roughly 1 in 1,000 to 5,000 people, though many cases go undiagnosed because symptoms can be subtle or absent for years.
What Happens Inside the Heart
Your heart muscle cells are held together by tiny structures called desmosomes, which act like rivets connecting neighboring cells. In ARVC, genetic mutations weaken these connections. Over time, the stressed and damaged muscle cells die and are replaced by fibrous scar tissue and fatty deposits. This process typically starts in specific areas of the right ventricle: the outflow tract (where blood exits toward the lungs), the area beneath the tricuspid valve, and the tip of the ventricle. Together, these three zones form what cardiologists call the “triangle of dysplasia.”
As more muscle is replaced, the affected areas stop contracting normally. They may bulge outward (forming small aneurysms) or simply stop moving altogether. The scar tissue also conducts electricity differently than healthy muscle, creating the conditions for short circuits that trigger fast, chaotic heart rhythms. These abnormal rhythms, particularly ventricular tachycardia, are what make ARVC dangerous.
The Genetic Roots of ARVC
ARVC is primarily caused by mutations in genes that build desmosomal proteins. Six genes account for 40 to 50 percent of diagnosed cases. The most commonly affected gene is PKP2, which produces a protein called plakophilin-2. Other involved genes produce desmoglein-2, desmocollin-2, desmoplakin, and plakoglobin, all components of the same cell-to-cell anchoring system.
The most common inheritance pattern is autosomal dominant, meaning a parent with the mutation has a 50 percent chance of passing it to each child. However, carrying the gene doesn’t guarantee developing the disease. Penetrance varies widely, which is why some family members with the same mutation develop severe symptoms while others remain healthy. In rare cases, particularly a variant called Naxos disease seen predominantly in Greece, ARVC follows a recessive pattern requiring mutations from both parents. Some patients carry mutations in two different genes simultaneously, which tends to produce more severe disease.
Symptoms and When They Appear
ARVC most commonly surfaces between the teens and early forties, though it can appear at any age. The hallmark symptoms are palpitations (a sensation of the heart racing or fluttering), lightheadedness, fainting, and shortness of breath. These episodes often occur during or just after physical exertion, when the heart is under greater demand.
In some cases, the first sign of ARVC is a cardiac arrest. This is part of what makes the condition so concerning: it is a recognized cause of sudden cardiac death in young athletes who may not have had any prior symptoms or diagnosis. Many people with early-stage ARVC have no symptoms at all, with the disease detectable only through careful testing.
How ARVC Is Diagnosed
There is no single test that confirms ARVC. Instead, doctors use a structured scoring system called the Task Force Criteria, which evaluates findings across six categories: structural heart changes, tissue abnormalities, electrical signal patterns on an EKG, rhythm disturbances, and family history or genetic testing. Each finding is classified as major or minor, and a definite diagnosis requires a specific combination of these findings.
EKG Findings
A standard 12-lead EKG often reveals the first clues. The most characteristic finding is T-wave inversion in the right-sided chest leads (V1 through V3), which reflects abnormal electrical recovery in the damaged right ventricle. When T-wave inversion extends beyond V3, it suggests more widespread disease and correlates with a higher risk of ventricular tachycardia.
A rarer but highly specific finding is the epsilon wave, a small, low-voltage blip that appears just after the main heartbeat signal in leads V1 through V3. It represents the sluggish electrical conduction through scar tissue. One study found epsilon waves in about 38 percent of ARVC patients on a standard EKG, and those who had them were significantly more likely to also have widespread T-wave inversion and ventricular tachycardia.
Cardiac MRI
Cardiac MRI is one of the most valuable tools for diagnosing ARVC because it provides detailed, three-dimensional images of the heart’s structure and movement. It can reveal wall motion abnormalities (areas that don’t contract properly), thinning of the right ventricular wall, fatty or fibrous tissue infiltration, and aneurysms. Finding aneurysms in the triangle of dysplasia is considered virtually diagnostic of ARVC. The MRI also measures the right ventricle’s size and pumping efficiency, both of which factor into the Task Force Criteria.
Genetic Testing and Family Screening
Identifying a known disease-causing mutation in a patient strengthens the diagnosis and opens the door to screening family members. Because ARVC can be silent for years, first-degree relatives of someone with the condition are typically offered genetic testing and periodic cardiac evaluations, even if they feel perfectly healthy.
Conditions That Look Similar
ARVC can be difficult to distinguish from a few other conditions. In athletes, the right ventricle naturally enlarges from years of training, which can mimic the structural changes seen in early ARVC. The key difference is that athletic remodeling produces uniform enlargement with normal wall motion, while ARVC causes patchy abnormalities and regional dysfunction.
Brugada syndrome, another inherited arrhythmia condition, can overlap with ARVC on an EKG. Both can show conduction delays and T-wave changes in the right-sided leads. However, Brugada syndrome is caused by a defect in sodium channels rather than desmosomes, and it classically produces a distinctive “coved” ST-segment elevation pattern. Some Brugada patients have even shown structural changes on MRI that resemble ARVC, including right ventricular dilation and fatty infiltration, which can make telling them apart challenging without comprehensive evaluation.
Treatment and Living With ARVC
Treatment focuses on two goals: preventing sudden cardiac death and controlling symptoms from abnormal heart rhythms.
For patients at significant risk, an implantable cardioverter-defibrillator (ICD) is the primary defense. This small device monitors the heart continuously and delivers a shock to restore normal rhythm if a life-threatening arrhythmia occurs. The difference it makes is stark: pooled data across multiple studies show that the annual rate of sudden cardiac death drops from about 7 per 1,000 in patients without an ICD to less than 1 per 1,000 in those with one. Risk factors that point toward ICD placement include fainting episodes, right ventricular dysfunction, a history of ventricular tachycardia, and the severity of diagnostic findings.
Medications play a supporting role. Beta-blockers are commonly prescribed to slow the heart rate and reduce the frequency of abnormal rhythms. When beta-blockers alone aren’t enough, other rhythm-stabilizing medications may be added, particularly to reduce the number of ICD shocks a patient experiences.
Why Exercise Restrictions Matter
One of the most important lifestyle changes for anyone with ARVC, or even those who carry a gene mutation without symptoms yet, is avoiding high-intensity and competitive exercise. This isn’t a vague precaution. Research consistently shows that vigorous physical activity accelerates the disease in a dose-dependent way: the harder and more frequently you exercise, the earlier symptoms appear and the worse outcomes tend to be.
One study found that patients who exercised at high intensity for more than three hours a week developed dangerous arrhythmias and right ventricular dysfunction significantly earlier than those who exercised moderately (one to three hours weekly), who in turn fared worse than those in the low-activity group. Exercise intensity, rather than total duration, appears to be the stronger predictor of problems. The mechanical stress of vigorous exertion is thought to accelerate the breakdown of already-weakened desmosomal connections, speeding up muscle damage and scar formation.
Current consensus guidelines recommend that anyone diagnosed with ARVC avoid competitive sports and high-intensity endurance activities. This also applies to people who test positive for a disease-causing gene but haven’t yet developed any signs of heart damage. Restricting intense activity early may significantly alter the disease’s trajectory over a lifetime. Low-to-moderate recreational activity is generally considered safer, though individual recommendations depend on the extent of disease involvement.
Long-Term Outlook
ARVC is a progressive condition, meaning the replacement of heart muscle with scar and fat continues over time. However, the pace of progression varies enormously from person to person, influenced by genetics, exercise habits, and treatment. Some patients live decades with well-managed disease, while others experience more rapid decline in heart function.
Several factors predict a higher risk of serious arrhythmias: male sex (roughly double the risk), significant right ventricular dysfunction, fainting at the time of diagnosis, a history of non-sustained ventricular tachycardia, and younger age at presentation. With ICD protection, regular monitoring, appropriate medications, and activity modification, many people with ARVC maintain a good quality of life. The condition requires lifelong management, but the tools available today are far more effective than they were even two decades ago.